Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults
| Autor: | Pavitra Keshavan, Johnny Beltran-Rodriguez, Xavier Sáez-Llorens, Daniela Toneatto, Ilhem Mensi, Jose Manuel Pascual Novoa Pizarro |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Adolescent 030106 microbiology Immunology Immunization Secondary MenACWY Booster dose Meningococcal vaccine Neisseria meningitidis Serogroup medicine.disease_cause Young Adult 03 medical and health sciences meningococcal vaccine 0302 clinical medicine medicine Humans Immunology and Allergy Serum Bactericidal Test 030212 general & internal medicine Young adult antibody persistence booster dose Pharmacology Vaccines Conjugate Reactogenicity biology business.industry Immunogenicity Vaccination Antibodies Bacterial Meningococcal Infections Titer biology.protein Female MenABCW Antibody business Immunologic Memory Bacterial Outer Membrane Proteins Research Paper |
| Zdroj: | Human Vaccines & Immunotherapeutics |
| ISSN: | 2164-554X 2164-5515 0245-1514 |
| DOI: | 10.1080/21645515.2018.1457595 |
| Popis: | This open-label, multicenter extension study (NCT02451514) assessed persistence of Neisseria meningitidis serogroups ABCWY antibodies 4 years after primary vaccination. Adolescents and young adults who previously received 2 doses of MenABCWY+OMV (Group III), 1 dose of MenACWY-CRM (Group VI), or newly-recruited vaccine-naïve participants (Group VII) were administered 1 (Group III) or 2 doses (Groups VI and VII) of MenABCWY+OMV, 1 month apart. Immunogenicity was assessed by human serum bactericidal assay (hSBA). Safety and reactogenicity were also evaluated. Percentages of participants with hSBA titers ≥8 (serogroups ACWY), ≥5 (serogroup B) and hSBA geometric mean titers (GMTs) were evaluated in all 129 enrolled participants (Group III: 33; Group VI: 46; Group VII: 50). Anti-ACWY antibody concentrations waned over 4 years post-vaccination, but remained above pre-vaccination concentrations. Similarly, levels of antibodies against serogroup B test strains also waned over 4 years post-vaccination, but remained above pre-vaccination concentrations for some strains. MenABCWY+OMV booster induced a robust anamnestic anti-ACWY response in Group III and VI and a good response against serogroup B test strains (≥82%) in Group III. In serogroup B-naïve participants (Groups VI and VII), anti-B responses to 2 doses of MenABCWY+OMV were less homogenous and lower than in Group III. MenABCWY+OMV was reactogenic, but well-tolerated. No safety concerns were identified. These findings indicate that although antibodies against N. meningitidis serogroups ABCWY waned over 4 years post-vaccination, exposure to a MenABCWY+OMV booster dose elicits an anamnestic response in adolescents previously exposed to the same or another multivalent meningococcal vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|